Drug DevelopmentAlkermes announced positive P1b data for '2680, a novel, orexin 2 receptor/OX2R agonist, showcasing statistically significant and clinically meaningful improvements in sleep latency.
Regulatory MilestonesPDUFA date for pitolisant in pediatric narcolepsy has been set, which may add six months to the exclusivity period for Wakix.
Strategic AcquisitionsHarmony Biosciences has acquired rights to an oral orexin-2 receptor agonist, enhancing its portfolio in the sleep space.